Cardiovascular disease
Conditions
Interventions
Scheme Optimization Group:Group with drug discontinuation for 3-5 days: Patients took 100 mg of aspirin and 75 mg of clopidogrel orally daily before the surgery. 3-5 days before the OPCABG operation,
Conventional Protocol Group:Group with drug discontinuation > 5 days: Patients took 100 mg of aspirin and 75 mg of clopidogrel orally daily before the surgery. Before OPCABG, clopidogrel was discontin
Sponsors
Zhongshan hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients who can provide written informed consent 2 Provide informed consent prior to any study specific procedure 3. Male and female patients, aged 18-80 years old 4. Indications for coronary artery bypass surgery: three-vessel coronary artery disease, left main stenosis, or two-vessel coronary artery disease with impaired left ventricular function 5. Patients received dual antiplatelet therapy with aspirin and clopidogrel for at least 3 days before admission
Exclusion criteria
Exclusion criteria: 1. Cardiogenic shock, hemodynamic instability 2. Patients requiring urgent revascularization 3. Need for concurrent cardiac surgery (e.g., valve replacement) 4. Take other antiplatelet or anticoagulant drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grade 3 or Grade 4 bleeding as defined by UDPB during the perioperative period; | — |
Secondary
| Measure | Time frame |
|---|---|
| TIMI bleeding;GUSTO bleeding;BARC type 4 CABG bleeding;Chest tube drainage volume after surgery;Perioperative transfusion;Perioperative neurological symptoms;Perioperative myocardial infarction;Perioperative stroke;Perioperative infection;Perioperative atrial fibrillation;Perioperative death;Perioperative renal dysfunction;Hospital stay;ICU stay;Hospitalization cost; | — |
Countries
China
Contacts
Public ContactRunhua Ma
Zhongshan hospital, Fudan University
Outcome results
None listed